On a roll, MacroGenics allies with Roche on a bispecific development campaign
Just weeks after signing a $900 million pact with Incyte for its early-stage PD-1 checkpoint, MacroGenics $MGNX is back with a new deal covering the development of bispecifics for a variety of diseases for Roche. Roche $RHHBY, which just bought out Ignyta for $1.7 billion, is paying a modest $10 million upfront for the pact and committing to up to $370 million in milestones.
The collaboration brings together the biotech’s DART platform and Roche’s CrossMAb and DutaFab technologies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.